BETRF — BetterLife Pharma Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1464165 ·
Last close
$0.21
Market Cap
$33.75M
52W High
$0.21
52W Low
$0.04
ADV30
178,843
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -561,395 | -609,257 | 242,428 | 28,576 | 6,676,796 |
| Jan 2026 | 0 | — | -437,008 | -380,547 | 219,903 | 12,570 | 6,706,283 |
| Oct 2025 | 0 | — | -389,215 | -409,014 | 291,127 | 7,962 | 6,456,866 |
| Jul 2025 | 0 | — | -511,630 | -494,476 | 229,340 | 22,163 | 6,040,439 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-347,773
Investing CF
—
Financing CF
$243,100
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-119,301,932
Inventory
—
Receivables
$9,198
ST Investments
—
EBIT TTM
$-665,190
Pretax Income TTM
$-835,452
Interest Exp TTM
$170,262
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | -1,808,600 | -1,495,492 | 219,903 | 6,706,283 | — | -625,455 |
| Jan 2025 | 0 | -4,724,931 | -3,520,288 | 224,963 | 7,587,112 | — | -2,021,752 |
| Jan 2024 | 0 | -3,209,889 | -2,889,032 | 324,746 | 8,020,513 | — | -2,472,410 |
| Jan 2023 | 0 | -9,257,441 | -9,016,201 | 74,727 | 7,608,197 | — | -1,503,512 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | $33.85M | $2.08 | — |
| LTRN | Lantern Pharma Inc. | $33.56M | $2.63 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $33.28M | $0.79 | — |
| LITS | Lite Strategy, Inc. | $32.66M | $0.96 | — |
| IXHL | Incannex Healthcare Inc. | $35.18M | $2.94 | — |
News headlines (Yahoo Finance, 1h cache)
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
2026-07-13 12:00 · Yahoo
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
2026-07-09 12:00 · Yahoo
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
2026-07-06 12:00 · Yahoo
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
2026-06-25 12:00 · Yahoo
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
2026-06-22 12:00 · Yahoo
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 12:00 · Yahoo
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
2026-01-06 13:00 · Yahoo
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
2025-12-11 13:00 · Yahoo
BetterLife Pharma Highlights Advantages of BETR-001 - a Potent Neuroplastogen
2025-12-04 13:00 · Yahoo
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor
2025-11-25 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.